Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model | BMC Cancer | Full Text

Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model | BMC Cancer | Full Text

Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model

Anticancer compound 3-bromopyruvate (3-BrPA) suppresses cancer cell growth via targeting glycolytic and mitochondrial metabolism. The malignant peripheral nerve sheath tumor (MPNST), a very aggressive, therapy...

Authors:Christian Linke, Markus Wösle and Anja Harder

Citation:BMC Cancer 2020 20:896

Content type:Research article

 

Published on: 18 September 2020

• ViewFull Text
 
• ViewPDF